Want to join the conversation?
$EW 2Q15 Call: Strong second quarter performance led by underlying sales growth of 18%, significant global TAVR therapy adaption drove our results and also boosted by surgical valve and critical care product lines. During the quarter, we are pleased to receive U.S. approval of SAPIEN 3.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?